在衰老和疾病中,诺拉德能神经调节
F Krohn1, E Lancini1, M Ludwig2
1German Center for Neurodegenerative Diseases (DZNE), Otto-von-Guericke University Magdeburg, Magdeburg, Germany; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Neuroscience and biobehavioral reviews
|July 12, 2023
概括
大脑主要的诺亚上腺素来源 - - 脑 (locus coeruleus,LC) 的退化在健康的衰老中是不清楚的. 早期的LC功能障碍可能导致阿尔茨海默氏症和帕金森病的发病.
科学领域:
- 神经科学是一个神经科学.
- 神经生物学 神经生物学 神经生物学
- 神经病理学神经病理学
背景情况:
- 核心位置 (locus coeruleus,LC) 是一个关键的大脑干核,是大脑中诺亚上腺素 (NA) 的主要来源.
- NA调节关键功能,包括认知,自主控制和免疫反应.
- 在健康衰老中LC退化的作用及其对神经退行性疾病 (如阿尔茨海默氏症 (AD) 和帕金森氏症 (PD) 的贡献) 需要进一步阐明.
研究的目的:
- 审查衰老,AD和PD中LC退化背后的机制.
- 突出早期诺亚上腺系统功能障碍在AD和PD病变发生过程中的潜在作用.
- 刺激对LC退化在其他神经退行性疾病中的更广泛相关性的研究.
主要方法:
- 这是一篇综述性文章,综合了现有的关于部和神经退行症的研究.
- 研究了衰老,AD和PD中LC退化的机制.
- 讨论了神经退行性疾病中诺亚上功能障碍和早期行为症状之间的联系.
主要成果:
- 在健康的衰老中LC退化的程度尚未完全理解.
- 诺拉基因功能障碍与AD和PD的病变发生有关.
- 早期的LC参与可以解释AD和PD中共享的临床前症状 (例如,睡眠障碍,神经精神问题).
结论:
- 源自LC的诺亚上腺系统的早期退化可能是AD和PD病变发生的关键因素.
- 了解LC退化机制对于开发神经退行性疾病的早期诊断和治疗策略至关重要.
- 这些发现对超越AD和PD的更广泛的神经退行性疾病有影响.
相关概念视频
01:26Aging
89
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
89
01:37Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
01:15Neurogenesis and Regeneration of Nervous Tissue
866
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
866
01:19The Effect of Aging on Tissues
2.2K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
2.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219